Ipsen: completes acquisition of Epizyme

(CercleFinance.com) - On Friday evening Ipsen announced that it has sealed an agreement to acquire all of the outstanding shares of Epizyme at a price of 1.
45 dollar each plus a guaranteed value certificate of 1 dollar per share, thereby expanding its oncology portfolio.

As part of the transaction, Ipsen is acquiring Epizyme's leading drug Tazverik, a first-in-class chemotherapy-free EZH2 inhibitor that received fast-track approval from the US FDA in 2020.

The company is also acquiring Epizyme's first-in-class oral SETD2 inhibitor drug candidate, EZM0414, which received FDA fast-track approval in 2021.



Copyright (c) 2022 CercleFinance.com. All rights reserved.